Singh Sweta, Sahu Chinmoy, Patel Sangram Singh, Singh Abhay, Yaduvanshi Nidhi
Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Indian J Crit Care Med. 2020 Dec;24(12):1213-1217. doi: 10.5005/jp-journals-10071-23573.
A rapid increase in multidrug-resistant (MDR) strains is being seen across the globe especially in the Southeast Asian region, including India. Carbapenems and colistin form the mainstay of treatment against gram-negative pathogens, especially extended-spectrum beta-lactamase (ESBL)- and metallo-beta-lactamse (MBL)-producing isolates. However, due to increased resistance to carbapenems and toxicity of colistin, especially in intensive care units (ICUs), carbapenem-sparing antibiotics like ceftriaxone-sulbactam-EDTA (CSE) combination needs to be evaluated.
Bacterial isolates cultured from various clinical samples from all ICUs for a period of 9 months were evaluated. Bacterial identification was performed by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and antibiotic susceptibility testing were performed by disk diffusion and E test method. Antibiogram of various antibiotics was noted. Extended-spectrum beta-lactamase- and MBL-producing bacteria were identified by phenotypic methods. Antibiotic sensitivity results of CSE were compared with the comparator drugs like colistin, carbapenems, and tigecycline in Enterobacteriaceae, spp., and spp. along with ESBL and MBL producers.
A total of 2,760 samples of blood, cerebrospinal fluid (CSF), respiratory samples, tissue, and pus were collected from ICUs with maximum isolates from pus (37%) followed by respiratory samples (31%) and blood (27%). and were the predominant gram-negative pathogens accounting for 56% of the isolates followed by spp. (23%) and spp. (15%). Extended-spectrum beta-lactamase screening was positive for 57% (1,069/1,877) isolates; whereas 43% (732/1,877) were MBL producers. According to the antibiotic susceptibility results, CSE was the most effective antibiotic showing 94% sensitivity for carbapenem-sensitive Enterobacteriaceae and 97% for carbapenem-resistant and spp. Among the other drugs, colistin was found to be the most effective showing almost 95% sensitivity in both the Enterobacteriaceae and non-Enterobacteriaceae group (both ESBL + OXA/NDM). Ceftriaxone-sulbactam-EDTA was also found much more effective (95%) as compared to Colistin (89%) toward ESBL- and MBL-producing strains of Enterobacteriaceae and non-Enterobacteriaceae group. Among the carbapenems, imipenem was the most effective drug against Enterobacteriaceae showing 34% sensitivity and ertapenem proved to be least effective.
In our present study, CSE emerged as a potent antibacterial agent against MDR gram-negative infections; both for ESBL as well as MBL producers. Hence, in light of present study, we strongly recommend inclusion of CSE in routine sensitivity panel and may be used as a carbapenem- and colistin-sparing drug and a promising option against ESBL and MBL producers especially in ICU.
Singh S, Sahu C, Patel SS, Singh A, Yaduvanshi N. A Comparative Sensitivity Study of "Ceftriaxone-Sulbactam-EDTA" and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit. Indian J Crit Care Med 2020;24(12):1213-1217.
全球范围内多重耐药(MDR)菌株正在迅速增加,尤其是在包括印度在内的东南亚地区。碳青霉烯类和黏菌素是治疗革兰氏阴性病原体的主要药物,特别是针对产超广谱β-内酰胺酶(ESBL)和金属β-内酰胺酶(MBL)的分离株。然而,由于对碳青霉烯类的耐药性增加以及黏菌素的毒性,特别是在重症监护病房(ICU)中,需要评估头孢曲松-舒巴坦-EDTA(CSE)等碳青霉烯类节省型抗生素。
对从所有ICU的各种临床样本中培养9个月的细菌分离株进行评估。通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)进行细菌鉴定,并通过纸片扩散法和E试验法进行抗生素敏感性测试。记录各种抗生素的抗菌谱。通过表型方法鉴定产超广谱β-内酰胺酶和MBL的细菌。将CSE的抗生素敏感性结果与对照药物如黏菌素、碳青霉烯类和替加环素在肠杆菌科、 属和 属中以及产ESBL和MBL的菌株进行比较。
从ICU共收集了2760份血液、脑脊液(CSF)、呼吸道样本、组织和脓液样本,其中脓液样本中的分离株最多(37%),其次是呼吸道样本(31%)和血液(27%)。 属和 属是主要的革兰氏阴性病原体,占分离株的56%,其次是 属(23%)和 属(15%)。超广谱β-内酰胺酶筛查中57%(1069/1877)的分离株呈阳性;而43%(732/1877)是MBL产生菌。根据抗生素敏感性结果,CSE是最有效的抗生素,对碳青霉烯敏感的肠杆菌科细菌显示出94%的敏感性,对碳青霉烯耐药的 属和 属细菌显示出97%的敏感性。在其他药物中,黏菌素被发现是最有效的,在肠杆菌科和非肠杆菌科组(包括ESBL + OXA/NDM)中均显示出近95%的敏感性。与黏菌素(89%)相比,头孢曲松-舒巴坦-EDTA对肠杆菌科和非肠杆菌科组中产ESBL和MBL的菌株也更有效(95%)。在碳青霉烯类中,亚胺培南是对抗肠杆菌科最有效的药物,敏感性为34%,而厄他培南被证明是最无效的。
在我们目前的研究中,CSE成为一种针对MDR革兰氏阴性感染的有效抗菌剂;对产ESBL和MBL的菌株均有效。因此,根据目前的研究,我们强烈建议将CSE纳入常规敏感性检测项目中,并可作为一种节省碳青霉烯类和黏菌素的药物,尤其是在ICU中,是对抗产ESBL和MBL菌株的一种有前景的选择。
Singh S, Sahu C, Patel SS, Singh A, Yaduvanshi N. “头孢曲松-舒巴坦-EDTA”与多种抗生素对重症监护病房革兰氏阴性菌分离株的比较敏感性研究。《印度重症监护医学杂志》2020;24(12):1213 - 1217。